reported in a propensity score-matched population-based cohort analysis that GLP-1 receptor agonist use in patients with MASLD and type 2 diabetes was associated with a lower risk of HCC (aHR: 0.55, 95%CI: 0.44-0.69) and all-cause mortality (aHR: 0.62, 95%CI: 0.55-0.71) [59]
Expert Opin Investig Drugs 24:12871298 Ginn C, Khalili H, Lever R, Brocchini S (2014) PEGylation and its impact on the design of new protein-based medicines
Looking for trusted guidance on your weight loss journey
Dietitians help you build a structured, nutrientdense, lowervolume eating pattern that fits your appetite, culture, budget and health conditions, rather than leaving you to live on dry crackers and hope for the best, and organisations experienced in GLP1 care, such as Ausclin, integrate this support into routine consultations
However, the speed at which it works can vary depending on the individual and their specific health conditions